BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult Participants
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 58
- Registration Number
- NCT05767398
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy
- Conditions
- Primary Membranous Nephropathy
- Interventions
- First Posted Date
- 2023-01-31
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 282
- Registration Number
- NCT05707377
- Locations
- 🇹🇷
Erciyes University Medical Faculty, Erciyes, Turkey
🇧🇷Ruschel Medicina E Pesquisa Clinica, Rio de Janeiro, Brazil
🇦🇷Investigacion Clinica Aplicada, Ciudad Autonoma Buenos Aires, Argentina
A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.
- Conditions
- Urothelial CarcinomaRenal Cell CarcinomaMelanomaNon-mucosal Melanoma
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 202
- Registration Number
- NCT05661955
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China
Safety, Pharmacokinetics and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab in Participants With Solid Tumors in Chinese Participants
- First Posted Date
- 2022-12-09
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05644626
Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
- First Posted Date
- 2022-12-07
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 111
- Registration Number
- NCT05640102
- Locations
- 🇺🇸
Clearview Cancer Institute, Huntsville, Alabama, United States
🇺🇸Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung CancerMetastatic Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 400
- Registration Number
- NCT05635708
- Locations
- 🇮🇹
Regina Elena, Istituto Nazionale Dei Tumori, Ifo, Irccs, Roma, Italy
🇮🇹Centro Ricerche Cliniche Di Verona, Verona, Italy
🇲🇾Tengku Ampuan Afzan Hospital, Kuantan, Malaysia
A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer
- Conditions
- Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 113
- Registration Number
- NCT05609370
- Locations
- 🇺🇸
Baptist Md Anderson Cancer Center, Jacksonville, Florida, United States
🇺🇸Alaska Oncology and Hematology, Llc, Anchorage, Alaska, United States
🇺🇸Banner Md Anderson Cancer Center, Gilbert, Arizona, United States
Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-10-13
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 121
- Registration Number
- NCT05577702
- Locations
- 🇨🇳
Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No Hospital), Ningbo, Zhejiang, China
🇨🇳The First Affiliated Hospital of Wannan Medical College, Wuhu, Anhui, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus Placebo as Adjuvant Treatment in Participants With Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: sitravatinib-matching placeboDrug: tislelizumab-matching placebo
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- BeiGene
- Registration Number
- NCT05564338
Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy Adults
- First Posted Date
- 2022-09-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 43
- Registration Number
- NCT05547399
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States